MAGEA3 and Miyoshi myopathy: A MAGE-A3 vaccine was studied in a phase II clinical trial in which MM patient T cells were stimulated in vivo with MAGE-A3 peptide vaccination, and subsequently apheresed and expanded ex vivo prior to re-infusion [157].